Abstract
Adjuvant endocrine therapy with tamoxifen or aromatase inhibitors (AIs) is widely prescribed after initial treatment for hormone-sensitive breast cancer — but we know little about the effects of such antiestrogen therapy on cognitive function. Researchers performed neuropsychological assessments in 179 postmenopausal Dutch women (mean age, 68) with estrogen- or progesterone-receptor–positive breast cancer who were enrolled in an international …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
